Date:2/10/2011

gyProprietary OncologyTREANDA393,473-393,473222,112-222,11277-77Other Proprietary Oncology20,86676,25697,12218,28175,36093,6411414Generic Oncology-22,99822,998-20,94020,940-1010Oncology414,33999,254513,593240,39396,300336,69372353OtherOther Proprietary15,1125,80920,92117,545-17,545(14)10019Other Generic13,220292,562305,78215,436108,922124,358(14)169146Other28,332298,371326,70332,981108,922141,903(14)174130$ 2,102,175$ 658,777$ 2,760,952$ 1,768,383$ 383,165$ 2,151,54819%72%28% Europe- Primarily Europe, Middle East and Africa Proprietary products are products which are sold under patent coverage.   Generic products are products sold without patent coverage in the primary sales territory. Patent coverage may exist in other territories.   CEPHALON, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(In thousands, except share data)(Unaudited) December 31, 20102009CURRENT ASSETS:   Cash and cash equivalents

$ 1,160,239$ 1,647,635   Receivables, net

431,333376,076   Inventory, net

291,360240,576   Deferred tax assets, net

213,798243,246   Other current assets

54,84558,423Total current assets

2,151,5752,565,956   INVESTMENTS ($155,808 at fair value in 2010)

168,49412,427   PROPERTY AND EQUIPMENT, net

502,856451,879   GOODWILL

822,071590,284   INTANGIBLE ASSETS, net

1,212,387981,857   DEBT ISSUANCE COSTS

14,19618,862   OTHER ASSETS

20,25436,830$ 4,891,833$ 4,658,095CURRENT LIABILITIES:   Current portion of long-term debt, net

$
51,997$
818,925   Accounts payable

104,47788,829   Accrued expenses

460,141430,209Total current liabilities

1,216,6151,337,963   LONG-TERM DEBT

391,416363,696   DEFERRED TAX LIABILITIES, net

172,589159,328   OTHER LIABILITIES

273,438111,728Total liabilities

2,054,0581,972,715REDEEMABLE EQUITY

170,183207,307E
'/>"/>

SOURCE Cephalon, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine technology :

1. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
2. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
3. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
4. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
5. Cephalon to Webcast Investor Day
6. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
7. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
8. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
9. Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
10. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
11. Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.